https://www.aigom.it/wp-content/uploads/2025/06/ART3.6.png1350960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-03 07:58:002025-06-03 07:58:00DATOPOTAMAB DERUXTECAN IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH ACTIONABLE GENOMIC ALTERATIONS: RESULTS FROM THE PHASE II TROPION-Lung05 STUDY.
https://www.aigom.it/wp-content/uploads/2025/05/ART27MAGGIO.png1411960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-27 08:00:382025-05-27 08:00:38PEMBROLIZUMAB AND CHEMOTHERAPY IN HIGH-RISK, EARLY-STAGE, ER+/HER2-BREAST CANCER: A RANDOMIZED PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/05/ART20.5.png1254841Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-20 09:51:122025-05-20 09:51:12DIAGNOSIS AND MANAGEMENT OF INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA: GUIDELINE ENDORSED BY ITALIAN SOCIETY OF INFECTION AND TROPICAL DISEASES (SIMIT), THE ITALIAN SOCIETY OF ANTI-INFECTIVE THERAPY (SITA), THE ITALIAN GROUP FOR ANTIMICROBIAL STEWARDSHIP (GISA), THE ITALIAN ASSOCIATION OF CLINICAL MICROBIOLOGIST (AMCLI) AND THE ITALIAN SOCIETY OF MICROBIOLOGY (SIM).
https://www.aigom.it/wp-content/uploads/2025/05/ART13.5.png1273960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-13 10:38:432025-05-13 10:38:43OlympiA: A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ADJUVANT OLAPARIB AFTER (NEO)ADJUVANT CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA1 AND/OR BRCA2 PATHOGENIC VARIANTS AND HIGH RISK HER2-NEGATIVE PRIMARY BREAST CANCER: LONGER TERM FOLLOW-UP
https://www.aigom.it/wp-content/uploads/2025/05/ART6MAGGIO.png1284923Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-06 08:45:352025-05-06 08:45:35FIRST-LINE MOBOCERTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH EGFR EXON 20 INSERTION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER IN THE PHASE III EXCLAIM-2 TRIAL
https://www.aigom.it/wp-content/uploads/2025/04/8-APRILE.png1301960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-08 07:56:242025-04-08 07:56:24CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2025/04/1aprile.png15431073Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-01 08:32:102025-04-01 08:32:10FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2025/03/25.3.png1215960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:16:212025-03-25 09:16:21PHASE II EFFICACY AND SAFETY OF 80 MG OSIMERTINIB IN PATIENTS WITH LEPTOMENINGEAL METASTASES ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (BLOSSOM).
https://www.aigom.it/wp-content/uploads/2025/03/IMM18.3.png1136960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-18 08:35:452025-03-18 08:35:45OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2025/03/LOC.11.3.png1342960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-11 08:47:002025-03-11 08:47:00FIRST-LINE NIVOLUMAB PLUS RELATLIMAB VERSUS NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA: AN INDIRECT TREATMENT COMPARISON USING RELATIVITY-047 AND CHECKMATE 067 TRIAL DATA.
